EDAP Showcases Innovative Devices at American Urology Annual Meeting
May 29 2012 - 7:00AM
Ablatherm-HIFU receives best poster
award
Unprecedented interest and attendance at
EDAP's booth from U.S. urologists
EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic
ultrasound, showcased its Ablatherm® High Intensity Focused
Ultrasound (HIFU) and its Sonolith i-move at the American
Urological Association (AUA) 2012 Annual Meeting held May 19-23 in
Atlanta, GA. A large number of U.S. urologists attended EDAP's
booth and device demonstrations.
Marc Oczachowski, Chief Executive Officer of EDAP TMS, remarked,
"We have been attending AUA for twenty years, and this year we
experienced record attendance and exceptional enthusiasm from U.S.
urologists at our booth. This year we estimate that approximately
80% of our booth traffic was from U.S. attendees, a major increase
from prior years when about half of booth traffic was from outside
the U.S. Most important, nearly all the U.S. doctors visiting our
booth expressed clear interest in both our ESWL and HIFU device
platforms."
Mr. Oczachowski continued, "U.S. urologists are aware of the
recent U.S. installations of our Sonolith i-move and are receiving
positive feedback from U.S. users. This demonstrates that, in
addition to our sales and marketing program, we are poised to
benefit from peer communication. Awareness levels are building for
the U.S. FDA filing for Ablatherm-HIFU as it approaches submission
later this year. Many urologists that visited our booth
inquired about ways to be prepared and educated about
Ablatherm-HIFU in order to be well positioned in advance of
potential approval and launch. We are very pleased to see
such strong momentum."
Marc Oczachowski concluded, "As an additional confirmation of
the global and scientific acceptance of Ablatherm-HIFU for the
treatment of localized prostate cancer, the poster presented by Dr.
Sebastien Crouzet from Edouard Herriot University Hospital, Lyon,
France, regarding the oncological outcomes from HIFU as a primary
care treatment for prostate cancer in 1098 patients, received the
best poster award for its session."
About EDAP TMS SA
EDAP TMS SA develops and markets Ablatherm®, the most advanced
and clinically proven choice for high-intensity focused ultrasound
(HIFU) treatment of localized prostate cancer. HIFU treatment
is shown to be a minimally invasive and effective treatment option
with a low occurrence of side effects. Ablatherm-HIFU is generally
recommended for patients with localized prostate cancer (stages
T1-T2) who are not candidates for surgery or who prefer an
alternative option, or for patients who failed radiotherapy
treatment. Approved in Europe as a treatment for prostate
cancer, Ablatherm-HIFU (High Intensity Focused Ultrasound) is
currently undergoing evaluation in a multi-center U.S. Phase II/III
clinical trial under an Investigational Device Exemption (IDE)
granted by the FDA, the ENLIGHT U.S. clinical study. The
Company also is developing this technology for the potential
treatment of certain other types of tumors. EDAP TMS SA also
produces and commercializes medical equipment (the Sonolith® range)
for treatment of urinary tract stones using extra-corporeal
shockwave lithotripsy (ESWL). For more information on the
Company, please visit http://www.edap-tms.com, and
http://www.hifu-planet.com.
Forward-Looking Statements
In addition to historical information, this press release
contains forward-looking statements that involve risks and
uncertainties. These include statements regarding the
Company's growth and expansion plans, the conclusiveness of the
results of and success of its Ablatherm-HIFU clinical trials and
expectations regarding the IDE submission to and approval by the
FDA of the Ablatherm-HIFU device. Such statements are based on
management's current expectations and are subject to a number of
uncertainties, including the uncertainties of the regulatory
process, and risks that could cause actual results to differ
materially from those described in these forward-looking
statements. Factors that may cause such a difference include,
but are not limited to, those described in the Company's filings
with the Securities and Exchange Commission and in particular, in
the sections "Cautionary Statement on Forward-Looking Information"
and "Risk Factors" in the Company's Annual Report on Form
20-F. Ablatherm-HIFU treatment is in clinical trials, but not
FDA-approved or marketed in the United States.
CONTACT: Blandine Confort
Investor Relations / Legal Affairs
EDAP TMS SA
+33 4 72 15 31 72
bconfort@edap-tms.com
Investors:
Stephanie Carrington
The Ruth Group
646-536-7017
scarrington@theruthgroup.com
EDAP TMS (NASDAQ:EDAP)
Historical Stock Chart
From Jun 2024 to Jul 2024
EDAP TMS (NASDAQ:EDAP)
Historical Stock Chart
From Jul 2023 to Jul 2024